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Background: Progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease caused by JC virus
(JCV), occurs mainly in immunocompromised patients. While JCV DNA is detected in the cerebrospinal fluid (CSF)
from a certain proportion of patients suspected of having PML, JCV-negative patients may also develop brain
lesions due to other infectious agents. This study assessed the prevalence of six herpesviruses in the CSF from
patients diagnosed with or suspected of PML.
Methods: Two hundred and ninety-nine CSF specimens and clinical data were collected from 255 patients, including
31 confirmed PML cases. Quantitative PCR assays were carried out to detect the genomic DNA of JCV, herpes simplex
virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6).
Results: Herpesvirus DNAs were detected in the CSF specimens from 29 of 255 patients (11.4%). HSV-1 and CMV were
detected in JCV-negative patients, whereas VZV and EBV were detected in both CSF JCV-positive and -negative
individuals. The herpesvirus-positive patients had underlying disorders that caused immunosuppression, such as HIV
infection, congenital immunodeficiencies, and hematologic malignancies, and presented with neurologic symptoms
and MRI lesions, mainly in the cerebral white matter. The median values of CSF cell counts and protein levels in the
herpesvirus-positive patients were slightly higher than those in the PML patients.
Conclusions: The results demonstrate that herpesviruses are occasionally detected in the CSF from PML patients and
immunocompromised individuals suspected of having PML. Thus, this study provides a significant basis for the
diagnosis and treatment of neurological disorders in immunocompromised patients.
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Progressive multifocal leukoencephalopathy (PML) is a
rare but fatal demyelinating disease of the central ner-
vous system (CNS) caused by JC virus (JCV), a small
DNA virus belonging to the family Polyomaviridae,
genus Polyomavirus [1-3]. Humans are infected with
JCV asymptomatically during childhood and are persist-
ently infected with it throughout life. From 50–90% of* Correspondence: nakamich@nih.go.jp
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article, unless otherwise stated.adults have been reported to be serologically positive for
JCV [1-4]. In some severely immunocompromised pa-
tients, JCV activates and causes a lytic infection in the
oligodendrocytes, leading to PML [1-4]. Although PML
is mainly diagnosed in patients with HIV-infection, it is
also observed in patients with immunodeficiency due to
a hematological malignancy, chemotherapy, transplant-
ation, lymphocyte depletion, or autoimmune disorders,
such as systemic lupus erythematosus, and in those
under treatment with immunosuppressive agents [1,3,5].
In addition, PML has recently been identified in patients
receiving immunomodulatory therapies with monoclonaltral Ltd. This is an Open Access article distributed under the terms of the
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mab [1-3,6].
The detection of JCV DNA in the cerebrospinal fluid
(CSF) by PCR is a reliable and less-invasive diagnostic
marker of PML, particularly when combined with typical
magnetic resonance imaging (MRI) patterns [1,7]. CSF
testing for JCV DNA using a quantitative PCR technique
has become the current diagnostic standard [6]. In Japan,
real-time PCR testing for JCV DNA in CSF specimens
has been partly supported by the Laboratory of Neuro-
virology, Department of Virology 1, National Institute of
Infectious Diseases (NIID), Tokyo, Japan, since 2007. The
CSF from approximately 11% of patients (48 of 419) was
found to be positive for JCV DNA and these patients
were diagnosed with PML [8]. However, no JCV could be
detected in the CSF samples from the remaining approxi-
mately 89% of patients, implying that a large proportion
of these subjects might have developed brain disorders
due to other infectious or non-infectious causes.
Herpesviruses, in particular, herpes simplex virus (HSV),
varicella-zoster virus (VZV), cytomegalovirus (CMV),
Epstein-Barr virus (EBV), or human herpesvirus 6 (HHV-
6), are major etiological agents of encephalitis and other
CNS infections in immunocompromised persons [9-13].
This study sought to assess whether these herpesviruses
contribute to the CNS involvement in patients diagnosed
with or suspected of having PML.
Methods
Collection of CSF specimens and clinical data
The study was conducted under the approval from the
Ethical Committee for Biomedical Science in the NIID
(approval number 339). Informed consent from patients
or their family members was also obtained. Patients sus-
pected of having PML on the basis of neurological
symptoms and/or MRI patterns were enrolled in this
study. Upon request to the patients’ physicians, CSF test-
ing for JCVDNA was routinely performed regardless of
patient age, gender, underlying disease, or medical his-
tory. Two hundred and ninety-nine CSF specimens were
collected by lumbar puncture from 255 patients from
April 2007 to the end of January 2010, immediately fro-
zen, and then transferred to the NIID for PCR testing.
For 44 of the patients, CSF testing was repeated during
their follow-up period. Clinical data were collected from
the patients’ physicians through standardized question-
naires. The following data were analyzed: age, gender,
underlying diseases, manifestations of neurologic symp-
toms, pattern of brain MRI lesions, and CSF leukocyte
counts and total protein levels.
Real-time PCR testing for viral DNA in CSF specimens
Total DNAs were extracted from the CSF specimens using
a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA)and then used as PCR templates as described previously
[8,14,15]. Since most of the CSF specimens had been frozen
at the hospitals, they also contained cellular components.
Quantitative real-time PCR assays targeting the DNAs of
JCV [8,14,15], VZV [16], CMV [17], and HHV-6 [17] were
carried out as described in the earlier reports. HSV-1/2 and
EBV DNAs were quantified using an artus HSV-1/2 LC
PCR Kit (Qiagen) and LightCycler EBV Quantification Kit
(Roche, Penzberg, Germany), respectively, according to the
protocols supplied by the manufacturers.
Statistical analysis
The detection rates of herpesvirus DNAs in the CSF speci-
mens and the sex ratios of patients in each group were sta-
tistically compared by means of a two-tailed Fisher’s exact
test. For multiple testing, the resulting P-value was cor-
rected using the Benjamini-Hochberg method. Differences
in the ages and CSF cell counts and protein contents be-
tween patient groups were compared by nonparametric
analyses using the Mann–Whitney U test. All P-values less
than 0.05 were judged to be statistically significant.
Results
Detection of JCV in CSF from patients suspected of
having PML
The study population comprised 166 males and 89
females. The mean age of the subjects was 56.3 years
(median 59.0 years, range 4–89 years, SD = 18.0), exclud-
ing 1 male patient whose age was not definitely stated.
The underlying diseases of 255 subjects were as follows:
HIV infection (n = 52, 50 males, 2 females), hematologic
disorders (n = 51, 39 males, 12 females), autoimmune
disorders (n = 33, 10 males, 23 females), other diseases
(n = 46, 29 males, 17 females), and unknown (n = 73, 38
males, 35 females). A total of 299 CSF specimens from
255 patients were subjected to the real-time PCR assay for
JCV DNA, and 42 samples (14%) were found to be positive
for JCV DNA. The median JCV load in these specimens
was 3.2 × 104 copies/mL (range 1.5 × 102 – 4.8 × 108 cop-
ies/mL, SD = 7.8 × 107). The prevalence of JCV DNA and
underlying diseases in the patient population are shown in
Table 1. Thirty-one of 255 patients (12%) were diagnosed
with PML based on clinical findings and JCV DNA-
positive CSF. These PML patients had HIV infection (10
patients, 19%), hematologic disorders (13 patients, 26%),
autoimmune disorders (3 patients, 9%), or other diseases
(5 patients, 11%). No JCV DNA was detected in the CSF
specimens from 73 patients who had no clinically apparent
underlying disorders.
Detection of herpesvirus DNA in CSF from patients
diagnosed with or suspected of having PML
The next series of analyses were conducted to clarify the
etiological contribution of herpesviruses to CNS disease
Table 1 Prevalence of CSF JCV DNA and underlying
diseases in the patient population
No. (%) of patients
Total JCV-positive
Underlying disease (n = 255) (n = 31)
HIV infection 52 10 (19.2)
Hematologic disease 51 13 (25.5)
Autoimmune disease 33 3 (9.1)
Other disease 46 5 (10.9)
Unknown 73 0 (0)
Figure 1 Viral loads of herpesvirus DNAs in the CSF specimens
from patients. The CSF viral loads of HSV-1, VZV, CMV, and EBV are
shown (left to right). Each open circle indicates the copy number of viral
DNA in each sample, and the horizontal lines represent the medians.
Table 3 Number of patients in whom herpesvirus DNA
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mens from 255 patients diagnosed with or suspected of
having PML. Among the 299 CSF samples, 31 were posi-
tive for herpesvirus DNA (Table 2). HSV-1, VZV, CMV,
and EBV were detected in 1 (0.3%), 8 (2.7%), 5 (1.7%),
and 19 (6.4%) specimens, respectively. Two specimens
were positive for CMV and either HSV-1 or EBV. No
amplification signal was observed for HSV-2 and HHV-6
in any sample. HSV-1 and CMV were detected only in
JCV-negative CSF specimens. In contrast, VZV and EBV
were detected in both JCV-positive and -negative sam-
ples. The viral DNA level of HSV-1 in 1 specimen was
1.3 × 103 copies/mL. The median viral loads of VZV,
CMV, and EBV were 3.3 × 102, 1.1 × 103, and 1.5 × 103
copies/mL, respectively (Figure 1). Although the DNA
levels of these viruses in most specimens ranged from
102 to 104 copies/mL, more than 104 copies/mL of VZV,
CMV, and EBV DNAs were found in some samples.
Proportion of patients for whom CSF specimens were
herpesvirus DNA positive
Table 3 shows the numbers and proportion of patients for
whom the CSF specimens were positive for herpesvirus
DNA. Among the 255 subjects, CSF herpesvirus DNA was
detected in 29 (11%). HSV-1 and CMV were detected in
CSF JCV-negative patients, while VZV and EBV were de-
tected in JCV-negative and positive-patients. The detectionTable 2 Number of herpesvirus DNA-positive and -negative
CSF specimens
No. (%) of CSF specimens
Herpesvirus Totala JCV-positive JCV-negative
DNA (n = 299) (n = 42) (n = 257)
HSV-1 1 (0.3) 0 (0) 1 (0.4)
HSV-2 0 (0) 0 (0) 0 (0)
VZV 8 (2.7) 1 (2.4) 7 (2.7)
CMV 5 (1.7) 0 (0) 5 (1.9)
HHV-6 0 (0) 0 (0) 0 (0)
EBV 19 (6.4) 5 (11.9) 14 (5.4)
aTwo specimens were positive for CMV and either HSV-1 or EBV DNA.rate of herpesvirus DNAs in JCV-positive patients (19%)
was higher than that in JCV-negative individuals (10%),
but this difference was not statistically significant. VZV
was detected in 8 patients, from one of whom EBV-
positive CSF specimens were obtained during the follow-
up. Five patients were found to be positive for CMV, and
HSV-1 and EBV were concomitantly detected in CMV-
positive samples from 1 patient each. Sixteen individuals
were found to be positive for EBV but not for other
herpesviruses. The EBV-positive rate appeared to be higher
than those of other herpesviruses. In addition, the detec-
tion rate of EBV in JCV-positive patients was statistically
higher than that in JCV-negative patients (P = 0.032).was detected in the CSF
No. (%) of patients
Herpesvirus Total CSF JCV-positive CSF JCV-negative
DNA in CSF (n = 255) (n = 31) (n = 224)
Total 29 (11.4) 6 (19.4) 23 (10.3)
HSV-1 and CMV 1 (0.4) 0 (0) 1 (0.4)
VZV 7 (2.7) 1 (3.2) 6 (2.7)
VZV or EBVa 1 (0.4) 0 (0) 1 (0.4)
CMV 3 (1.2) 0 (0) 3 (1.3)
CMV and EBV 1 (0.4) 0 (0) 1 (0.4)
EBV 16 (6.3) 5 (16.1) 11 (4.9)
aVZV and EBV DNA was detected in different CSF specimens collected from
the same patient during the follow-up period.
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The clinical data of 29 herpesvirus DNA-positive patients
were analyzed. The patients comprised 23 males and 6 fe-
males. The mean age of all except 1 patient was 52.5 years
(median 53.5 years, range 30–84 years, SD = 14.7). There
were no statistically significant differences in the age
and sex ratios between the herpesvirus DNA-positive
and -negative patients. The underlying diseases of the pa-
tients who provided herpesvirus DNA-positive CSF speci-
mens are summarized in Table 4. Of the 29 patients, 27
(93%) were found to have underlying disorders that may
cause immunosuppression. Sixteen patients (55%) had
HIV infection, and the severe loss of peripheral blood
CD4-positive T cells was observed in most cases. VZV,
CMV, and/or EBV were detected in CSF from the HIV-
positive patients. Eight patients (28%) suffered from hema-
tologic diseases, such as non-Hodgkin’s lymphoma and
aplastic anemia, and had been treated with hematopoietic
stem cell transplantation, combination chemotherapy, or
other immunosuppressive drugs. Three patients (10%) had
other underlying diseases, such as lupus nephritis, chronic
renal failure, or primary angiitis of the CNS, and received
immunosuppressive therapy. Among the subjects in each
group, the proportion of the herpesvirus DNA-positive
patients with HIV infection (31%) and that with hema-
tologic diseases (16%) were statistically higher than that
with other underlying diseases (4%), as compared by mul-
tiple statistical testing (P = 0.000 and 0.048, respectively).
In addition, both JCV and herpesvirus DNAs were de-
tected in the CSF specimens from 6 patients with either
HIV infection or hematologic diseases.
Clinical features of herpesvirus DNA-positive patients
In the final set of analyses, the clinical features of the pa-
tients with herpesvirus-positive CSF were compared to
those of PML patients. Table 5 shows the appearance
patterns of neurologic symptoms and brain lesions. In
the study population, 25 patients were positive for JCV
but provided herpesvirus-negative CSF specimens. TheseTable 4 Underlying diseases of patients in whom herpesvirus
Herpesvirus No. of patients
DNA in CSF HIV infection H
Total 29 16 (55.2)
HSV-1 and CMV 1 0 (0)
VZV 7 2b (28.6)
VZV or EBV 1 1 (100)
CMV 3 3 (100)
CMV and EBV 1 0 (0)
EBV 16 10c (62.5)
aThe data include patients with autoimmune disorders.
bOne patient was positive for JCV.
c,dThe results include 2 and 3 JCV-positive patients, respectively.PML patients presented with diverse neurologic symp-
toms, such as paralysis, dementia, dysarthria, dysphagia,
and/or visual impairment (data not shown). MRI lesions
were found mainly in the cerebral white matter (CWM)
(84%), and a smaller proportion of patients showed le-
sions in other sites, such as the cerebellum (16%) and
brain stem (28%). Among the 24 patients in whom her-
pesviruses were detected in the CSF, 20 individuals (83%)
had neurologic manifestations. MRI lesions were identified
in the CWM (75%), cerebellum (29%), brain stem (8%),
and other sites (13%). There were no statistically signifi-
cant differences in the proportion of individuals with
lesions at each site between the PML and herpesvirus-
positive patients. The VZV- or EBV-positive patients dis-
played lesions not only in the CWM, but also in other
areas of the brain. In contrast, the lesions were localized
in the CWM in the HSV-1- and/or CMV-positive patients.
Figure 2 shows the results of CSF cell counts and total
protein contents of the PML and CSF herpesvirus-positive
patients. Since the CSF cell counts and/or total protein
contents were not defined in the questionnaires in some
cases, the numbers of patients are not identical in
Figure 2A and 2B. In both patient groups, the median
values of cell counts for both mono- and polynuclear cells
(Figure 2A) and protein contents (Figure 2B) were at nor-
mal or near-normal levels. However, a considerable pro-
portion of herpesvirus-positive patients exhibited higher
cell numbers and protein levels when compared to those
of PML patients, and these differences were statistically
significant (P = 0.049 and 0.004, respectively).
Discussion
The present study aimed to comprehensively assess the
prevalence of six human herpesviruses in the CSF speci-
mens from patients diagnosed with or suspected of having
PML. Since the aim of this study was the detection of
herpesviruses DNA using PCR from the CSF samples of
the patients diagnosed with or suspected PML associated
with several immuno-suppressive underlying diseases, theDNA was detected in the CSF
Underlying disease (%)
ematologic disease Other diseasea Unknown
8 (27.6) 3 (10.3) 2 (6.9)
1 (100) 0 (0) 0 (0)
3 (42.9) 2 (28.6) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 1 (100) 0 (0)
4d (25.0) 0 (0) 2 (12.5)







matterViral DNA in CSF Cerebellum Brain stem Other Unknown
JCVb 25 25 (100) 21 (84.0) 4 (16.0) 7 (28.0) 2 (8.0) 2 (8.0)
Herpesvirusesc 24 20 (83.3) 18 (75.0) 7 (29.2) 2 (8.3) 3 (12.5) 1 (4.2)
HSV-1 and CMV 1 1 (100) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0)
VZV 6 6 (100) 5 (83.3) 1 (16.7) 1 (16.7) 0 (0) 1 (16.7)
VZV or EBV 1 1 (100) 1 (100) 1 (100) 0 (0) 1 (100) 0 (0)
CMV 3 2 (66.7) 3 (100) 0 (0) 0 (0) 0 (0) 0 (0)
CMV and EBV 1 1 (100) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0)
EBV 12 9 (75.0) 7 (58.3) 5 (41.7) 1 (8.3) 2 (16.7) 0 (0)
aThe data include patients with multiple lesion sites.
bThe patients were negative for herpesvirus DNA in their CSF.
cThe patients were negative for JCV DNA in their CSF.
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ruses, but the data do not always indicate the main contri-
bution to brain damage.
One of the most important findings is that EBV was
present in the CSF of approximately 16% of the con-
firmed PML patients. Although the detection of EBV as
well as JCV in the CSF has been reported previously
[18-20], the prevalence of EBV in the CSF specimens
from the relatively large number of patients suspected of
having PML has not been determined previously. This
data suggest that it is not rare to concomitantly detect
JCV and EBV in PML cases. Although the EBV-positive
patients had not been diagnosed with EBV-related diseases
when the specimens were collected, it would be interest-
ing to see whether these patients later developed EBV-
associated neurological disorders. It would be attractive to
hypothesize that EBV infection is involved in the progres-
sion of PML progression as the detection rate of EBV inFigure 2 CSF cell counts (A) and total protein contents (B) in PML and
total protein contents were not defined in the questionnaires in some case
data of patients positive for both CSF JCV and herpesvirus DNAs are not in
within each box is the median; the lower and upper boundaries are the 25
range; and dots and arrows show outliers.the CSF from JCV-positive patients was higher than that
in JCV-negative patients. However, this result might be
due to differences in the proportion of immunocomprom-
ised individuals between the JCV-negative and -positive
populations. VZV was detected in the CSF from one PML
patient with AIDS (CD4 cell count, 8 cells/μl). The detec-
tion rate of VZV appeared to be lower than that of EBV,
and the co-detection of JCV and VZV in CSF was re-
ported in one previous report [20]. It is possible that this
patient developed both PML and VZV encephalitis.
It is of interest to note that HSV-1/2, CMV, and HHV-
6 were not detected in the CSF specimens from any
PML patient. Two previous reports demonstrated that
JCV was concomitantly detected with CMV or HSV-1 in
the CSF [20,21]. The data obtained in this study indicate
that the CSF from some PML patients was HSV-1 and/
or CMV DNA-positive, although the prevalence was
low. Another important finding in this study is thatherpesvirus-positive patients. Since the CSF cell counts and/or
s, the numbers of patients are not identical in panels A and B. The
cluded in each panel. In box-and-whisker plots, the thick horizontal line
th and 75th percentiles, respectively; vertical whiskers extend over the
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than 10% of the CSF specimens from patients suspected
of having but not diagnosed with PML. Based on neuro-
logical symptoms, MRI lesion patterns, and underlying
disease, it seems reasonable that these patients were sus-
pected of having PML. A large proportion of the patients
that were found to be positive for herpesviruses had HIV
infection or hematologic disorders, suggesting that there
is a significant relationship between the presence of her-
pesviruses in the CSF and severe immunosuppression
due to AIDS, chemotherapy, or hematopoietic stem cell
transplantation. As the distribution of CSF cell numbers
and protein contents partially overlapped in the PML
and herpesvirus-positive patients, these parameters may
not directly contribute to a diagnosis of PML. It is likely
that the inflammatory response was inhibited under the
immunosuppressive conditions in both patient groups.
However, it is worth focusing on the significant propor-
tion of the herpesvirus-positive patients showing high
CSF cell counts. In these patients, it can be postulated
that the brain inflammation was induced by the lytic
herpesvirus infection. In such a situation, the amount of
herpesvirus DNA might be increased by the migration of
the infected cells into the CSF, as the PCR assays were
performed using total DNA extracted from frozen CSF.
In some herpesvirus-positive cases, a combination of
two herpesviruses, such as CMV and HSV-1, CMV and
EBV, and VZV and EBV, were detected in the CSF, which
is consistent with previous reports describing the co-
detection of herpesviruses in CSF [18,20,22,23]. It was
also observed that VZV and EBV were detected in differ-
ent CSF specimens from one patient during the follow-
up period. This patient presented with lesions in the
CWM and basal ganglia, at which time VZV was de-
tected. At repeat CSF testing 3 months later, EBV, but
not VZV, was detected in the CSF, and lesions were
identified in the CWM and cerebellum. This observation
indicates that although VZV propagation in the CNS
was reduced, EBV infection or reactivation occurred
during the follow-up period in this patient.
Currently, no specific treatment has been established for
PML. Restoration of the immune system, either by com-
bination antiretroviral therapy for patients with AIDS or
by moderating the immunosuppressive therapies for non-
AIDS patients, is the only treatment option for the
management of PML, although several experimental
treatments are being investigated [1]. In contrast, acyclovir
is effective in the treatment of encephalitis caused by HSV
or VZV [24]. It is also known that ganciclovir and
foscarnet are beneficial for patients with CMV-related en-
cephalitis [24]. Thus, the present data suggest that com-
prehensive testing for these herpesviruses as well as JCV is
important for early diagnosis and proper management of
patients suspected of having PML.Conclusions
In summary, as herpesviruses can contribute to CNS dis-
orders in a significant proportion of patients suspected of
having PML, comprehensive testing for the herpesviruses
as well as for JCV is required for the accurate diagnosis
and treatment of CNS diseases in patients diagnosed with
or suspected of having PML.
Abbreviations
PML: Progressive multifocal leukoencephalopathy; CNS: Central nervous
system; JCV: JC virus; CSF: Cerebrospinal fluid; HSV: Herpes simplex virus;
VZV: Varicella-zoster virus; CMV: Cytomegalovirus; EBV: Epstein-Barr virus;
HHV-6: Human herpesvirus 6; MRI: Magnetic resonance imaging;
NIID: National Institute of Infectious Diseases; CWM: Cerebral white matter.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KN and MS conceived of the study. KN and NI carried out real-time PCR
testing, and KN created the database of patients. KN analyzed the clinical data
and drafted the manuscript. TS performed the statistical analyses. MS, NI, TS, IK,
and CKL participated in the study design and coordination, and helped to draft
the manuscript. All authors read and approved the final manuscript.
Acknowledgments
The authors are grateful to all study participants and physicians who
contributed to the present study. This work was partly supported by Grants-
in-Aid for the Research Committee of Prion Disease and Slow Virus Infection
(H22-Nanchi-Ippan-013), the Research for Intractable Infectious Diseases in
Organ Transplant Recipients (H21-Shinko-Ippan-009), and the Research on
HIV/AIDS (H24-AIDS-Wakate-002) from the Ministry of Health, Labour and
Welfare of Japan. The authors declare that they have no conflicting interests.
Author details
1Department of Virology 1, National Institute of Infectious Diseases, Toyama
1-23-1, Shinjuku-ku, Tokyo 162-8640, Japan. 2Department of Ecosocial System
Engineering, Interdisciplinary Graduate School of Medicine and Engineering,
University of Yamanashi, Takeda 4-3-11, Kofu City 400-8511, Yamanashi,
Japan.
Received: 26 September 2013 Accepted: 5 December 2013
Published: 13 December 2013
References
1. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A: Progressive multifocal
leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol
2010, 6:667–679.
2. Tan CS, Koralnik IJ: Progressive multifocal leukoencephalopathy and other
disorders caused by JC virus: clinical features and pathogenesis.
Lancet Neurol 2010, 9:425–437.
3. Shishido-Hara Y: Progressive multifocal leukoencephalopathy and
promyelocytic leukemia nuclear bodies: a review of clinical,
neuropathological, and virological aspects of JC virus-induced demyelinating
disease. Acta Neuropathol 2010, 120:403–417.
4. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, Miller E:
Population-based study of antibody to the human polyomaviruses BKV
and JCV and the simian polyomavirus SV40. J Med Virol 2003, 71:115–123.
5. Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M, Fux CA, Vernazza P,
Bernasconi E, Battegay M, Hirsch HH: Incidence and outcome of
progressive multifocal leukoencephalopathy over 20 years of the Swiss
HIV Cohort Study. Clin Infect Dis 2009, 48:1459–1466.
6. Major EO: Progressive multifocal leukoencephalopathy in patients on
immunomodulatory therapies. Annu Rev Med 2010, 61:35–47.
7. Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R,
De Luca A: Reduced rate of diagnostic positive detection of JC virus DNA
in cerebrospinal fluid in cases of suspected progressive multifocal
leukoencephalopathy in the era of potent antiretroviral therapy. J Clin
Microbiol 2005, 43:4175–4177.
Nakamichi et al. BMC Neurology 2013, 13:200 Page 7 of 7
http://www.biomedcentral.com/1471-2377/13/2008. Nakamichi K, Mizusawa H, Yamada M, Kishida S, Miura Y, Shimokawa T,
Takasaki T, Lim CK, Kurane I, Saijo M: Characteristics of progressive
multifocal leukoencephalopathy clarified through internet-assisted
laboratory surveillance in Japan. BMC Neurol 2012, 12:121.
9. Kleinschmidt-DeMasters BK, Gilden DH: The expanding spectrum of
herpesvirus infections of the nervous system. Brain Pathol 2001, 11:440–451.
10. Steiner I: Herpes simplex virus encephalitis: new infection or
reactivation? Curr Opin Neurol 2011, 24:268–274.
11. Fujimoto H, Asaoka K, Imaizumi T, Ayabe M, Shoji H, Kaji M: Epstein-Barr
virus infections of the central nervous system. Intern Med 2003, 42:33–40.
12. Ivers LC, Kim AY, Sax PE: Predictive value of polymerase chain reaction of
cerebrospinal fluid for detection of Epstein-Barr virus to establish the
diagnosis of HIV-related primary central nervous system lymphoma.
Clin Infect Dis 2004, 38:1629–1632.
13. Weber T, Frye S, Bodemer M, Otto M, Luke W: Clinical implications of
nucleic acid amplification methods for the diagnosis of viral infections
of the nervous system. J Neurovirol 1996, 2:175–190.
14. Nakamichi K, Kurane I, Saijo M: Evaluation of a quantitative real-time PCR
assay for the detection of JC polyomavirus DNA in cerebrospinal fluid
without nucleic acid extraction. Jpn J Infect Dis 2011, 64:211–216.
15. Nakamichi K, Kishida S, Tanaka K, Suganuma A, Sano Y, Sano H, Kanda T,
Maeda N, Kira J, Itoh A, Kato N, Tomimoto H, Kurane I, Lim CK, Mizusawa H,
Saijo M: Sequential changes in the non-coding control region sequences
of JC polyomaviruses from the cerebrospinal fluid of patients with
progressive multifocal leukoencephalopathy. Arch Virol 2013, 158:639–650.
16. Hawrami K, Breuer J: Development of a fluorogenic polymerase chain
reaction assay (TaqMan) for the detection and quantitation of varicella
zoster virus. J Virol Methods 1999, 79:33–40.
17. Ogawa H, Suzutani T, Baba Y, Koyano S, Nozawa N, Ishibashi K, Fujieda K,
Inoue N, Omori K: Etiology of severe sensorineural hearing loss in
children: independent impact of congenital cytomegalovirus infection
and GJB2 mutations. J Infect Dis 2007, 195:782–788.
18. Weinberg A, Bloch KC, Li S, Tang YW, Palmer M, Tyler KL: Dual infections of the
central nervous system with Epstein-Barr virus. J Infect Dis 2005, 191:234–237.
19. Corcoran C, Rebe K, van der Plas H, Myer L, Hardie DR: The predictive value
of cerebrospinal fluid Epstein-Barr viral load as a marker of primary
central nervous system lymphoma in HIV-infected persons. J Clin Virol
2008, 42:433–436.
20. Kannangai R, Sachithanandham J, Mahadevan A, Abraham AM, Sridharan G,
Desai A, Ravi V, Shankar SK: Association of neurotropic viruses in HIV-
infected individuals who died of secondary complications of tuberculosis,
cryptococcosis, or toxoplasmosis in South India. J Clin Microbiol 2013,
51:1022–1025.
21. d’Arminio Monforte A, Cinque P, Vago L, Rocca A, Castagna A, Gervasoni C,
Terreni MR, Novati R, Gori A, Lazzarin A, Moroni M: A comparison of brain
biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients.
J Neurol 1997, 244:35–39.
22. Davies NW, Brown LJ, Gonde J, Irish D, Robinson RO, Swan AV, Banatvala J,
Howard RS, Sharief MK, Muir P: Factors influencing PCR detection of
viruses in cerebrospinal fluid of patients with suspected CNS infections.
J Neurol Neurosurg Psychiatry 2005, 76:82–87.
23. Cinque P, Vago L, Dahl H, Brytting M, Terreni MR, Fornara C, Racca S, Castagna
A, Monforte AD, Wahren B, Lazzarin A, Linde A: Polymerase chain reaction on
cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases
of the central nervous system in HIV-infected patients. AIDS 1996,
10:951–958.
24. Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, Hartman BJ,
Kaplan SL, Scheld WM, Whitley RJ: The management of encephalitis:
clinical practice guidelines by the Infectious Diseases Society of America.
Clin Infect Dis 2008, 47:303–327.
doi:10.1186/1471-2377-13-200
Cite this article as: Nakamichi et al.: Detection of human herpesviruses
in the cerebrospinal fluid from patients diagnosed with or suspected of
having progressive multifocal leukoencephalopathy. BMC Neurology
2013 13:200.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
